<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098618</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02638</org_study_id>
    <secondary_id>6258-04-9R0</secondary_id>
    <secondary_id>NCI-6553</secondary_id>
    <secondary_id>CDR0000398171</secondary_id>
    <secondary_id>U01CA099118</secondary_id>
    <nct_id>NCT00098618</nct_id>
  </id_info>
  <brief_title>Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer</brief_title>
  <official_title>A Phase 2 Study Of BAY 43-9006 In Combination With Interferon Alfa-2b In Metastatic Renal Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for their&#xD;
      growth or by blocking blood flow to the tumor. Interferon alfa may interfere with the growth&#xD;
      of tumor cells and slow the growth of kidney cancer. Sorafenib may help interferon alfa kill&#xD;
      more tumor cells by making tumor cells more sensitive to the drug. Giving sorafenib together&#xD;
      with interferon alfa may kill more tumor cells. This phase II trial is studying how well&#xD;
      giving sorafenib with interferon alfa works in treating patients with locally advanced or&#xD;
      metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the feasibility and tolerability of sorafenib and interferon alfa in patients&#xD;
      with locally advanced or metastatic renal cell carcinoma.&#xD;
&#xD;
      II. Determine the response rate (complete response and partial response) in patients treated&#xD;
      with this regimen.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the progression-free survival and response duration of patients treated with&#xD;
      this regimen.&#xD;
&#xD;
      II. Correlate changes in laboratory parameters with response in patients treated with this&#xD;
      regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral sorafenib twice daily and interferon alfa subcutaneously three times a&#xD;
      week for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients with stable or responding disease are followed every 3 months for 2 years, every 6&#xD;
      months for 2 years, and then annually for 1 year or until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 10 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2004</start_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (CR+PR) using RECIST criteria</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>CR+PR rate will be calculated with exact 90% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 3+ toxicities assessed using NCI CTCAE version 3.0</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Toxicities will be tabulated by type and grade. Toxicity rates will be calculated with exact 90% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Kaplan-Meier curves will be used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Kaplan-Meier curves will be used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented , assessed up to 5 years</time_frame>
    <description>Kaplan-Meier curves will be used.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Papillary Renal Cell Carcinoma</condition>
  <condition>Recurrent Renal Cell Cancer</condition>
  <condition>Stage III Renal Cell Cancer</condition>
  <condition>Stage IV Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (sorafenib tosylate and recombinant interferon alfa)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sorafenib twice daily and interferon alfa subcutaneously three times a week for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (sorafenib tosylate and recombinant interferon alfa)</arm_group_label>
    <other_name>BAY 43-9006</other_name>
    <other_name>BAY 43-9006 Tosylate Salt</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>SFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (sorafenib tosylate and recombinant interferon alfa)</arm_group_label>
    <other_name>Alferon N</other_name>
    <other_name>alpha interferon</other_name>
    <other_name>IFN-A</other_name>
    <other_name>Intron A</other_name>
    <other_name>Roferon-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sorafenib tosylate and recombinant interferon alfa)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed renal cell carcinoma&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
               -  All histologic subtypes allowed&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques&#xD;
                  OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  No known brain metastases or leptomeningeal disease&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  No bleeding diathesis&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of sensitivity to E. coli-derived products&#xD;
&#xD;
          -  No history of severe depression&#xD;
&#xD;
          -  No active infection requiring antibiotics&#xD;
&#xD;
          -  No seizure disorder requiring antiepileptic medication&#xD;
&#xD;
          -  No medical condition likely to require systemic corticosteroids&#xD;
&#xD;
          -  No autoimmune disorder that could result in life-threatening complications&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No more than 1 prior biologic response modifier regimen&#xD;
&#xD;
          -  At least 4 weeks since prior biologic response modifiers&#xD;
&#xD;
          -  No prior interferon alfa&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy to non-index lesions&#xD;
&#xD;
               -  Prior radiotherapy to index lesion allowed provided irradiated lesion progressed&#xD;
                  ≥ 20% in diameter&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation therapy&#xD;
&#xD;
               -  Concurrent prophylactic anticoagulation, such as low-dose warfarin, for venous or&#xD;
                  arterial access device allowed provided PT, PTT, and INR are normal&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel George</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>December 7, 2004</study_first_submitted>
  <study_first_submitted_qc>December 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2004</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

